Our investigation provides molecular evidence for the fibrotic role of LPCs in the liver and suggests that the Activin A-Smad-CTGF/CCN2 axis in LPCs may be a potential therapeutic target of liver fibrosis. The gene discussed is CCN2; the disease is Hepatic fibrosis.